Brokers Set Expectations for TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for TG Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings per share of $0.72 for the year. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TGTX has been the subject of several other research reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Down 0.3 %

Shares of TGTX opened at $29.04 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The stock has a market cap of $4.52 billion, a price-to-earnings ratio of -290.37 and a beta of 2.24. The firm has a 50 day simple moving average of $31.54 and a 200-day simple moving average of $26.03.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter last year, the business posted $0.73 earnings per share. The business’s revenue was down 49.4% compared to the same quarter last year.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NBC Securities Inc. grew its stake in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares during the period. Blue Trust Inc. boosted its position in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics in the 3rd quarter valued at $53,000. Values First Advisors Inc. acquired a new stake in TG Therapeutics in the 3rd quarter valued at $58,000. Finally, Synergy Asset Management LLC purchased a new position in TG Therapeutics in the fourth quarter valued at about $75,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,358 shares of company stock valued at $781,497. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.